E R Copson1, R I Cutress2, T Maishman2, B K Eccles2, S Gerty2, L Stanton2, D G Altman3, L Durcan2, C Wong2, P D Simmonds2, L Jones4, D M Eccles2. 1. Cancer Sciences Academic Unit and University of Southampton Clinical Trials Unit, Faculty of Medicine, University of Southampton and University Hospital Southampton Foundation Trust, Tremona Road, Southampton. Electronic address: e.copson@soton.ac.uk. 2. Cancer Sciences Academic Unit and University of Southampton Clinical Trials Unit, Faculty of Medicine, University of Southampton and University Hospital Southampton Foundation Trust, Tremona Road, Southampton. 3. Centre for Statistics in Medicine, Wolfson College Annexe, Oxford. 4. Tumour Biology Department, Institute of Cancer, Barts and The London School of Medicine and Dentistry, Charterhouse Square, London, UK.
Abstract
BACKGROUND: Obese breast cancer patients have a poorer prognosis than non-obese patients. We examined data from a large prospective cohort study to explore the associations of obesity with tumour pathology, treatment and outcome in young British breast cancer patients receiving modern oncological treatments. PATIENTS AND METHODS: A total of 2956 patients aged ≤40 at breast cancer diagnosis were recruited from 126 UK hospitals from 2001 to 2007. Height and weight were measured at registration. Tumour pathology and treatment details were collected. Follow-up data were collected at 6, 12 months, and annually. RESULTS: A total of 2843 eligible patients (96.2%) had a body mass index (BMI) recorded: 1526 (53.7%) were under/healthy-weight (U/H, BMI <25 kg/m(2)), 784 (27.6%) were overweight (ov, BMI ≥25 to <30), and 533 (18.7%) were obese (ob, BMI ≥30). The median tumour size was significantly higher in obese and overweight patients than U/H patients (Ob 26 mm versus U/H 20 mm, P < 0.001; Ov 24 mm versus U/H 20 mm, P < 0.001). Obese and overweight patients had significantly more grade 3 tumours (63.9% versus 59.0%, P = 0.048; Ov 63.6% versus U/H 59.0% P = 0.034) and node-positive tumours (Ob 54.6% versus U/H 49.0%, P = 0.027; Ov 54.2% versus U/H 49%, P = 0.019) than U/H patients. Obese patients had more ER/PR/HER2-negative tumours than healthy-weight patients (25.0% versus 18.3%, P = 0.001). Eight-year overall survival (OS) and distant disease-free interval (DDFI) were significantly lower in obese patients than healthy-weight patients [OS: hazard ratio (HR) 1.65, P < 0.001; DDFI: HR 1.44, P < 0.001]. Multivariable analyses adjusting for tumour grade, size, nodal, and HER2 status indicated that obesity was a significant independent predictor of OS and DDFI in patients with ER-positive disease. CONCLUSIONS: Young obese breast cancer patients present with adverse tumour characteristics. Despite adjustment for this, obesity still independently predicts DDFI and OS.
BACKGROUND:Obese breast cancerpatients have a poorer prognosis than non-obesepatients. We examined data from a large prospective cohort study to explore the associations of obesity with tumour pathology, treatment and outcome in young British breast cancerpatients receiving modern oncological treatments. PATIENTS AND METHODS: A total of 2956 patients aged ≤40 at breast cancer diagnosis were recruited from 126 UK hospitals from 2001 to 2007. Height and weight were measured at registration. Tumour pathology and treatment details were collected. Follow-up data were collected at 6, 12 months, and annually. RESULTS: A total of 2843 eligible patients (96.2%) had a body mass index (BMI) recorded: 1526 (53.7%) were under/healthy-weight (U/H, BMI <25 kg/m(2)), 784 (27.6%) were overweight (ov, BMI ≥25 to <30), and 533 (18.7%) were obese (ob, BMI ≥30). The median tumour size was significantly higher in obese and overweight patients than U/H patients (Ob 26 mm versus U/H 20 mm, P < 0.001; Ov 24 mm versus U/H 20 mm, P < 0.001). Obese and overweight patients had significantly more grade 3 tumours (63.9% versus 59.0%, P = 0.048; Ov 63.6% versus U/H 59.0% P = 0.034) and node-positive tumours (Ob 54.6% versus U/H 49.0%, P = 0.027; Ov 54.2% versus U/H 49%, P = 0.019) than U/H patients. Obesepatients had more ER/PR/HER2-negative tumours than healthy-weight patients (25.0% versus 18.3%, P = 0.001). Eight-year overall survival (OS) and distant disease-free interval (DDFI) were significantly lower in obesepatients than healthy-weight patients [OS: hazard ratio (HR) 1.65, P < 0.001; DDFI: HR 1.44, P < 0.001]. Multivariable analyses adjusting for tumour grade, size, nodal, and HER2 status indicated that obesity was a significant independent predictor of OS and DDFI in patients with ER-positive disease. CONCLUSIONS: Young obese breast cancerpatients present with adverse tumour characteristics. Despite adjustment for this, obesity still independently predicts DDFI and OS.
Authors: Francesco Giallauria; Alessandra Vitelli; Luigi Maresca; Maria Santucci De Magistris; Paolo Chiodini; Amalia Mattiello; Marco Gentile; Maria Mancini; Alessandra Grieco; Angelo Russo; Rosa Lucci; Giorgio Torella; Franco Berrino; Salvatore Panico; Carlo Vigorito Journal: Intern Emerg Med Date: 2015-05-28 Impact factor: 3.397
Authors: Stephanie L Greville-Heygate; Tom Maishman; William J Tapper; Ramsey I Cutress; Ellen Copson; Alison M Dunning; Linda Haywood; Louise J Jones; Diana M Eccles Journal: JCO Precis Oncol Date: 2020-05-04
Authors: Vidar G Flote; Riyas Vettukattil; Tone F Bathen; Thore Egeland; Anne McTiernan; Hanne Frydenberg; Anders Husøy; Sissi E Finstad; Jon Lømo; Øystein Garred; Ellen Schlichting; Erik A Wist; Inger Thune Journal: Lipids Health Dis Date: 2016-03-12 Impact factor: 3.876
Authors: Manuel Picon-Ruiz; Cynthia Morata-Tarifa; Janeiro J Valle-Goffin; Eitan R Friedman; Joyce M Slingerland Journal: CA Cancer J Clin Date: 2017-08-01 Impact factor: 508.702